Chronic phencyclidine (PCP)-induced modulation of muscarinic receptor mRNAs in rat brain : Impact of antipsychotic drug treatment (Q45331619)

13 December 2017

title

Chronic phencyclidine (PCP)-induced modulation of muscarinic receptor mRNAs in rat brain: impact of antipsychotic drug treatment (English)

1 reference

13 December 2017

Chronic phencyclidine (PCP)-induced modulation of muscarinic receptor mRNAs in rat brain : Impact of antipsychotic drug treatment (English)

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

3 December 2024

Lucinda J. Steward

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21640736

3 December 2024

Matthew D. Kennedy

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21640736

3 December 2024

Brian J. Morris

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21640736

3 December 2024

Judith A. Pratt

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21640736

3 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21640736

3 December 2024

publication date

27 May 2011

1 reference

full work available at URL

13 December 2017

https://api.elsevier.com/content/article/PII:S0028390811002061?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

https://api.elsevier.com/content/article/PII:S0028390811002061?httpAccept=text/plain

3 December 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

3 December 2024

1 reference

13 December 2017

1 reference

13 December 2017

1 reference

13 December 2017

page(s)

1554-1563

1 reference

Muscarinic potentiation of excitatory amino acid-evoked dopamine release in mesencephalic cells: specificity for the NMDA response and role of intracellular messengers

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Tissue concentrations of clozapine and its metabolites in the rat

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Effect of phencyclidine on [3H]QNB binding

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Identification of a family of muscarinic acetylcholine receptor genes

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

In primary neuronal cultures muscarinic m1 and m3 receptor mRNA levels are regulated by agonists, partial agonists and antagonists

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Potential role of muscarinic receptors in schizophrenia

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Muscarinic mechanisms of antipsychotic atypicality

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Drugs with anticholinergic properties: a potential risk factor for psychosis onset in Alzheimer's disease?

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Effect of chronic neuroleptic treatment on central and peripheral muscarinic receptors

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Glutamate and schizophrenia: beyond the dopamine hypothesis

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation.

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia.

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Decreased striatal release of acetylcholine following withdrawal from long-term treatment with haloperidol: modulation by cholinergic, dopamine-D1 and -D2 mechanisms

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Primary structure of rat cardiac beta-adrenergic and muscarinic cholinergic receptors obtained by automated DNA sequence analysis: further evidence for a multigene family

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Specificity in the projection patterns of accumbal core and shell in the rat.

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Cholinergic systems and schizophrenia: primary pathology or epiphenomena?

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Involvement of the pallidal-thalamocortical circuit in adaptive behavior

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Functional specificity of ventral striatal compartments in appetitive behaviors

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Muscarinic antagonists attenuate dizocilpine-induced hypermotility in mice

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

D2 dopamine receptor gene expression by cholinergic neurons in the rat striatum

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

The inositol 1,4,5-trisphosphate pathway mediates cholinergic potentiation of rat hippocampal neuronal responses to NMDA

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Opposing short- and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Structure of the m1 muscarinic acetylcholine receptor gene and its promoter

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Modelling prefrontal cortex deficits in schizophrenia: implications for treatment

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Role of the cholinergic system in the pathology and treatment of schizophrenia.

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia.

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Chronic treatment with first or second generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Role of the central cholinergic system in the therapeutics of schizophrenia

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Multiplicity of muscarinic autoreceptor subtypes? Comparison of the distribution of cholinergic cells and cells containing mRNA for five subtypes of muscarinic receptors in the rat brain.

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Phencyclidine-induced alteration in rat muscarinic cholinergic receptor regulation

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Negative symptoms and hypofrontality in chronic schizophrenia

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Involvement of the cholinergic system in haloperidol-induced release of dopamine from slices of striatum in the rat.

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

On the significance of subterritories in the "accumbens" part of the rat ventral striatum

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

Effects of typical and atypical antipsychotic drugs on rat brain muscarinic receptors

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2011.05.016

3 December 2024

Identifiers

1 reference

13 December 2017

1 reference